<DOC>
	<DOCNO>NCT01399788</DOCNO>
	<brief_summary>This bioequivalence trial evaluate bioequivalence Myrin P Forte reference drug healthy volunteer .</brief_summary>
	<brief_title>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin , Isoniazid , Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>Healthy , male female , 21 55 year age , body weight less 55 kg , Body mass index ( BMI ) 17.5 30.5 kg/m2 . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead electrocardiogram ( ECG ) clinical laboratory test . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) , positive Hepatitis B surface antigen Human Immunodeficiency Virus ( HIV ) serology result . pregnant nursing female , alcohol , drug , smoke user , sensitive study medication relate component , History active gout , History active tuberculosis , Known optic neuritis ophthalmological condition .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>